Top News Stories

  • 177Lu-Dotatate for advanced midgut neuroendocrine tumors

    on January 12th, 2017
    FROM THE NEW ENGLAND JOURNAL OF MEDICINE 177Lu-Dotatate, a radionuclide related to octreotide, reduced the risk of disease progression or death by 79% in a phase III trial involving 229 adults with advanced, progressive midgut neuroendocrine tumors, investigators reported in the New England Journal [...]
  • Type 2 risk increases with number of GDM pregnancies

    on January 11th, 2017
    FROM OBSTETRICS & GYNECOLOGY (FRONTLINE MEDICAL NEWS) In women with prior mild gestational diabetes, subsequent pregnancies did not increase the frequency of metabolic syndrome but did increase the risk of type 2 diabetes, according to a review of 426 women 5-10 years after a GDM pregnancy. The [...]
  • Antiplatelet agents reduce preterm birth risk in some groups

    on January 11th, 2017
    FROM OBSTETRICS & GYNECOLOGY The use of antiplatelet agents in pregnant women at risk for preeclampsia reduces the risk of spontaneous preterm birth by about 7%, while moderate to very preterm birth at less than 34 weeks of gestation is reduced by 14%. Those are key findings from a meta-analysis[...]
  • Survey: Docs see health care improvements as unlikely in 2017

    on January 10th, 2017
    Physicians appear to be quite pessimistic about the chances for improving health care quality, costs, and access in 2017, according to a survey conducted by InCrowd, a market insights technology firm. Of the 150 physicians who responded to the 3-minute “mobile microsurvey” conducted on Dec. 4, 2[...]
  • What’s in store for CMS under Seema Verma?

    on January 10th, 2017
    AT THE AMERICAN BAR ASSOCIATION HEALTH LAW SUMMIT WASHINGTON (FRONTLINE MEDICAL NEWS)– Big changes could be in store for the Medicaid program under the potential leadership of Seema Verma as administrator of the Centers for Medicare & Medicaid Services. In nominating Ms. Verma, President-elect[...]
  • Historic HIV vaccine efficacy study underway in South Africa

    on January 10th, 2017
    The first HIV vaccine efficacy study to launch anywhere in 7 years is testing whether an experimental vaccine safely prevents HIV infection among South African adults. According to an announcement by the National Institute of Allergy and Infectious Diseases, a cofunder of the trial and part of the U[...]
  • USPSTF reaffirms need for folic acid supplements in pregnancy

    on January 10th, 2017
    FROM JAMA The U.S. Preventive Services Task Force continues to recommend that all women planning or capable of pregnancy should take a daily supplement of 0.4-0.8 mg of folic acid to prevent neural tube defects in their offspring. The task force “concludes with high certainty” that the benefits [...]
  • High levels of flu activity in 10 U.S. states

    on January 9th, 2017
    The 2016-2017 flu season shifted into high gear at the end of calendar year 2016, as four states were reported to be at the highest level of flu activity and six others were close behind, according to the Centers for Disease Control and Prevention. For the week ending Dec. 31, 2016, Georgia, New Jer[...]
  • United States about to top 40,000 Zika cases

    on January 9th, 2017
    The number of pregnant women with laboratory evidence of Zika infection jumped up a bit at the end of 2016, and the United States approached 40,000 Zika cases among all Americans at the beginning of the new year, according to reports from the Centers for Disease Control and Prevention. There were 18[...]
  • ‘Weekend warrior’ exercise pattern sufficient to cut mortality

    on January 9th, 2017
    FROM JAMA INTERNAL MEDICINE The “weekend warrior” exercise pattern – having one or two rather than five to seven leisure-time activity sessions per week – may be sufficient to reduce all-cause, cardiovascular disease, and cancer mortality risks, according to a report published online Jan. 9 [...]
  • First drug for spinal muscular atrophy approved

    on January 6th, 2017
    The antisense oligonucleotide drug nusinersen is the first therapy approved by the U.S. Food and Drug Administration to treat children and adults with spinal muscular atrophy. The drug was developed by Ionis Pharmaceuticals and will be marketed by Biogen under the brand name Spinraza. The antisense [...]
  • In NSCLC, delayed chemo yields survival benefit comparable to early chemo

    on January 6th, 2017
    FROM JAMA ONCOLOGY Patients with non–small-cell lung cancer (NSCLC) for whom adjuvant chemotherapy must be delayed for as long as 18 weeks have mortality outcomes that are no worse than those of patients who start chemotherapy soon after surgery, and those who undergo delayed chemotherapy have a s[...]
  • NIAID panel: Introduce peanut foods early to cut allergy risk

    on January 5th, 2017
    FROM THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY Introducing peanut foods to children who are at different levels of risk for peanut allergies may prevent or mitigate the risk, and the strategies for clinicians are explained in new guidelines issued by an expert panel sponsored by the National In[...]
Back to top